Inositols in PCOS
Open accessThe DOI matches its Crossref record; 143 of the 147 references it cites were found in a registry or an index.
Abstract
(1) Background: Myoinositol (MI) and D-chiro-inositol (DCI) are involved in a number of biochemical pathways within oocytes having a role in oocyte maturation, fertilization, implantation, and post-implantation development. Both inositols have a role in insulin signaling and hormonal synthesis in the ovaries. (2) Methods: Literature search (with key words: inositols, myo-inositol, d-chiro-inositol, PCOS) was done in PubMed until Sept. 2020 and 197 articles were identified, of which 47 were of clinical trials (35 randomized controlled trials). (3) Results: Many studies have demonstrated that in patients with polycystic ovarian syndrome (PCOS) MI treatment improved ovarian function and fertility, decreased the severity of hyperandrogenism including acne and hirsutism, positively affected metabolic aspects, and modulated various hormonal parameters deeply involved in the reproductive axis function and ovulation. Thus treating with MI has become a novel method to ameliorate PCOS symptoms, improve spontaneous ovulation, or induce ovulation. The current review is focused on the effects of MI and DCI alone or in combination with other agents on the pathological features of PCOS with focus on insulin resistance and adverse metabolic outcomes. (4) Conclusions: The available clinical data suggest that MI, DCI, and their combination in physiological ratio 40:1 with or without other compound could be beneficial for improving metabolic, hormonal, and reproductive aspects of PCOS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 (a) Effects of myoinositol and D-chiroinositol on glucose metabolism in PCOS (adapted from [68]). (b) Effects of myoinositol and D-chiroinositol on hormonal synthesis in PCOS.](https://figures.cochat.ai/paper-figures/9dd0bedcafd0485a835f08372099aad1/inositols-in-pcos-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“On the other hand, insulin resistance (IR) has a central role in its pathogenesis [5–7].”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Papaleo, E., Unfer, V., Baillargeon, J.-P., Fusi, F., Occhi, F., & De Santis, L. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.01.088 · Cited by 197 · cited 1×
“The trials assessing this combination show improved reproductive [100], hormonal, and metabolic disturbances in PCOS patients [95,97,108,123].”
BackgroundRetracted- Retracted
Pacchiarotti, A., Carlomagno, G., Antonini, G., & Pacchiarotti, A. (2016) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1101444 · Cited by 111
RetractedRETRACTED: Treatment of hirsutism with myo-inositol: a prospective clinical study
Minozzi, M., D'Andrea, G., & Unfer, V. (2008) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)60248-9 · Cited by 56 · cited 2×
“Some studies have demonstrated that MI treatment in patients with PCOS improved ovarian function and fertility [98–109], decreased the severity of hyperandrogenism, acne, and hirsutism [78,96,102], and positively affected metabolic parameters and modulated various hormonal parameters deeply involved in the reproductiv…”
BackgroundMethodRetracted(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
The Diagnosis of Polycystic Ovary Syndrome during Adolescence
Witchel, S. F., Oberfield, S., Rosenfield, R. L., Codner, E., Bonny, A., Ibáñez, L., Pena, A., Horikawa, R., Gomez-Lobo, V., Joel, D., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000375530 · Cited by 3,113
Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis*
Dunaif, A. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0318 · Cited by 2,458 · cited 1×
“The patients with PCOS both with and without obesity have higher prevalence of insulin resistance compared to healthy controls [19], although insulin resistance is more severe in obese subjects [20].”
BackgroundAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143 · cited 2×
“The use of Rotterdam criteria is advised by the two recent guidelines [7,9] both recognizing that Androgen Excess Society (AES) [1] criteria may correspond better to the pathogenesis of this disorder, as the AES emphasizes the importance Molecules 2020, 25, 5566; doi:10.3390/molecules25235566 www.mdpi.com/journal/mole…”
MethodInfluentialProfound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967 · cited 1×
“It affects muscle and fat tissue and the liver, but not the polycystic ovary itself [39,40].”
BackgroundTeede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., & the International PCOS Network (2018) · Clinical Endocrinology · doi:10.1111/cen.13795 · Cited by 1,823
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Rosenfield, R. L., & Ehrmann, D. A. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1104 · Cited by 1,603 · cited 1×
“Currently there is enough data supporting the fact that increased androgen production is based on primary defect in steroid production from the theca-cells [10].”
BackgroundTeede, H., Deeks, A., & Moran, L. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-41 · Cited by 1,565 · cited 2×
“None of the diagnostic criteria include however the metabolic disturbances (insulin resistance and overweight/obesity), that are often found in PCOS patients and could play a crucial role in the pathogenesis of the syndrome [2,3,5,7,9].”
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., Andersen, M., Azziz, R., et al. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.05.004 · Cited by 1,325
Prevalence and Characteristics of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome
Apridonidze, T., Essah, P. A., Iuorno, M. J., & Nestler, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1045 · Cited by 931
Obesity and the polycystic ovary syndrome
Gambineri, A., Pelusi, C., Vicennati, V, Pagotto, U., & Pasquali, R. (2002) · International Journal of Obesity · doi:10.1038/sj.ijo.0801994 · Cited by 836 · cited 15×
“In a small patient cohort (n = 40) De Cicco et al. [129] demonstrated that the combination of MI +ALA for 6 months decreased BMI, waist-hip ratio, hirsutism score, AMH, ovarian volume, and antral follicle count, and an increase in the number of menstrual cycles.”
BackgroundInfluentialThe Insulin-Related Ovarian Regulatory System in Health and Disease
Poretsky, L., Cataldo, N. A., Rosenwaks, Z., & Giudice, L. C. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.4.0374 · Cited by 818 · cited 1×
“Decreasing insulin levels on the other hand has no significant effect on LH secretion [53].”
BackgroundNESTLER, J. E., POWERS, L. P., MATT, D. W., STEINGOLD, K. A., PLYMATE, S. R., RITTMASTER, R. S., CLORE, J. N., & BLACKARD, W. G. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-1-83 · Cited by 815 · cited 8×
“Insulin can directly stimulate androgen secretion and/or increase lutein hormone (LH)-induced androgen secretion from the theca-cells [35,36], increase the amplitude of LH pulsatile secretion [34], decrease liver production of sex hormone binding globulin (SHBG) [37] (Figure 1).”
BackgroundInfluentialNestler, J. E., & Jakubowicz, D. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350902 · Cited by 743 · cited 1×
“Hyperinsulinemia appears to play an important pathogenic role in the hyperandrogenism and anovulation of both obese and lean women with PCOS [33,34].”
BackgroundLegro, R. S., Finegood, D., & Dunaif, A. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.5054 · Cited by 673
BARBIERI, R. L., MAKRIS, A., RANDALL, R. W., DANIELS, G., KISTNER, R. W., & RYAN, K. J. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-62-5-904 · Cited by 630 · cited 1×
“Increased insulin levels act synergistically with LH to stimulate ovarian production of androgens [38,48] and suppresses SHBG production from the liver [49], that leads to increased free testosterone levels.”
BackgroundGoodman, N. F., Cobin, R. H., Futterweit, W., Glueck, J. S., Legro, R. S., & Carmina, E. (2015) · Endocrine Practice · doi:10.4158/ep15748.dsc · Cited by 623
Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.
Rebar, R., Judd, H. L., Yen, S. S., Rakoff, J., Vandenberg, G., & Naftolin, F. (1976) · Journal of Clinical Investigation · doi:10.1172/jci108400 · Cited by 622
Nestler, J. E., Jakubowicz, D. J., Falcon de Vargas, A., Brik, C., Quintero, N., & Medina, F. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.6.4886 · Cited by 617 · cited 3×
“Increased insulin levels act synergistically with LH to stimulate ovarian production of androgens [38,48] and suppresses SHBG production from the liver [49], that leads to increased free testosterone levels.”
BackgroundDUNAIF, A., GRAF, M., MANDELI, J., LAUMAS, V., & DOBRJANSKY, A. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-65-3-499 · Cited by 586 · cited 1×
“Insulin resistance and hyperinsulinemia are more prevalent in anovulatory patients [32,45,56,57].”
BackgroundEvidence for Distinctive and Intrinsic Defects in Insulin Action in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Shelley, D. R., Green, G., Dobrjansky, A., & Licholai, T. (1992) · Diabetes · doi:10.2337/diab.41.10.1257 · Cited by 546 · cited 1×
“It affects muscle and fat tissue and the liver, but not the polycystic ovary itself [39,40].”
BackgroundOvulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary Syndrome
Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., & Allan, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401703 · Cited by 518 · cited 4×
“DCI 1200 mg daily [68] • Improved insulin sensitivity • Decreased BP • Decreased TG concentrations • Decreased serum androgen concentrations”
InfluentialTaylor, A. E., McCourt, B., Martin, K. A., Anderson, E. J., Adams, J. M., Schoenfeld, D., & Hall, J. E. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4105 · Cited by 494 · cited 1×
“Lean patients with PCOS, oligo-anovulation, and hyperandrogenemia can have normal insulin sensitivity, but more frequently have increased LH levels than those with obesity [45,58].”
BackgroundCONWAY, G. S., HONOUR, J. W., & JACOBS, H. S. (1989) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1989.tb00446.x · Cited by 445 · cited 3×
“Many studies demonstrate elevated plasma levels of LH and decreased of FSH in 30% to 90% of the cases [44,45].”
BackgroundCarmina, E., Rosato, F., Jannì, A., Rizzo, M., & Longo, R. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1457 · Cited by 420
Impact of Obesity on the Risk for Polycystic Ovary Syndrome
Yildiz, B. O., Knochenhauer, E. S., & Azziz, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1834 · Cited by 401 · cited 1×
“The prevalence of obesity in PCOS varies between 30% and 70% depending on ethnicity and criteria for PCOS diagnosis [26,27].”
BackgroundAbdominal adiposity and the polycystic ovary syndrome
Escobar-Morreale, H. F., & Millán, J. L. S. (2007) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2007.07.003 · Cited by 386 · cited 15×
“In a small patient cohort (n = 40) De Cicco et al. [129] demonstrated that the combination of MI +ALA for 6 months decreased BMI, waist-hip ratio, hirsutism score, AMH, ovarian volume, and antral follicle count, and an increase in the number of menstrual cycles.”
BackgroundInfluentialWillis, D., Mason, H., Gilling-Smith, C., & Franks, S. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550768 · Cited by 371 · cited 2×
“In cell cultures they demonstrate normal secretion of estradiol and progesterone in response to physiologic concentrations of insulin, that implies normal insulin sensitivity [41,43].”
BackgroundNestler, J. E., & Jakubowicz, D. J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4431 · Cited by 368
ADASHI, E. Y., HSUEH, A. J. W., & YEN, S. S. C. (1981) · Endocrinology · doi:10.1210/endo-108-4-1441 · Cited by 366 · cited 1×
“Insulin increases both basal and GNRH-stimulated secretion of LH and FSH in isolated pituitary cell cultures [50,51], but not in vivo [52].”
BackgroundCARA, J. F., & ROSENFIELD, R. L. (1988) · Endocrinology · doi:10.1210/endo-123-2-733 · Cited by 336 · cited 1×
“Insulin can directly stimulate androgen secretion and/or increase lutein hormone (LH)-induced androgen secretion from the theca-cells [35,36], increase the amplitude of LH pulsatile secretion [34], decrease liver production of sex hormone binding globulin (SHBG) [37] (Figure 1).”
BackgroundThe role of lifestyle modification in polycystic ovary syndrome
Norman, R. J., Davies, M. J., Lord, J., & Moran, L. J. (2002) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(02)00612-4 · Cited by 326 · cited 1×
“The prevalence of obesity in PCOS varies between 30% and 70% depending on ethnicity and criteria for PCOS diagnosis [26,27].”
BackgroundPregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis
Kjerulff, L. E., Sanchez-Ramos, L., & Duffy, D. (2011) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2011.03.021 · Cited by 300 · cited 1×
“[116] indicated that pregnancy in PCOS patients is associated with increased risk of gestational diabetes (GDM), pregnancy-induced hypertension, preeclampsia, and other pregnancy-related complications and thus PCOS is an established risk factor for gestational diabetes [117].”
BackgroundRobinson, S., Kiddy, D., Gelding, S. V., Willis, D., Niththyananthan, R., Bush, A., Johnston, D. G., & Franks, S. (1993) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1993.tb02376.x · Cited by 283 · cited 2×
“The severity of hyperinsulinema directly correlates to the severity of PCOS [31,32], but it is uncertain whether hyperandrogenemia results from insulin resistance or vice versa or if both conditions are independently developed.”
BackgroundMcLaughlin, T., Allison, G., Abbasi, F., Lamendola, C., & Reaven, G. (2004) · Metabolism · doi:10.1016/j.metabol.2003.10.032 · Cited by 268 · cited 1×
“In most studies its prevalence is between 44% and 75% [15–17], which is much higher than 10–25% observed in young healthy individuals [18].”
BackgroundBarber, T. M., Wass, J. A. H., McCarthy, M. I., & Franks, S. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02764.x · Cited by 254 · cited 1×
“Insulin resistance and hyperinsulinemia are more prevalent in anovulatory patients [32,45,56,57].”
BackgroundRice, S., Christoforidis, N., Gadd, C., Nikolaou, D., Seyani, L., Donaldson, A., Margara, R., Hardy, K., & Franks, S. (2005) · Human Reproduction · doi:10.1093/humrep/deh609 · Cited by 229 · cited 1×
“In cell cultures they demonstrate normal secretion of estradiol and progesterone in response to physiologic concentrations of insulin, that implies normal insulin sensitivity [41,43].”
BackgroundMorin-Papunen, L. C., Vauhkonen, I., Koivunen, R. M., Ruokonen, A., & Tapanainen, J. S. (2000) · Human Reproduction · doi:10.1093/humrep/15.6.1266 · Cited by 227
Genazzani, A. D., Lanzoni, C., Ricchieri, F., & Jasonni, V. M. (2008) · Gynecological Endocrinology · doi:10.1080/09513590801893232 · Cited by 221 · cited 2×
“[79] demonstrated the same effect in overweight PCOS women —HOMA reduction from 2.”
BackgroundMethodTaylor, A. E. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.7.2248 · Cited by 211
Follicular dynamics in the polycystic ovary syndrome
Franks, S., Mason, H., & Willis, D. (2000) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(99)00239-7 · Cited by 202 · cited 1×
“The presence of big polycystic ovaries with high antral (2–8 mm) follicle number is one of the main characteristics of PCOS [54].”
BackgroundDeeks, A. A., Gibson-Helm, M. E., Paul, E., & Teede, H. J. (2011) · Human Reproduction · doi:10.1093/humrep/der071 · Cited by 202
Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials
Unfer, V., Facchinetti, F., Orrù, B., Giordani, B., & Nestler, J. (2017) · Endocrine Connections · doi:10.1530/ec-17-0243 · Cited by 188 · cited 2×
“[83] also demonstrated slight trend toward testosterone decrease with respect to controls, whereas androstenedione levels remained unchanged.”
MethodMyo-inositol in patients with polycystic ovary syndrome: A novel method for ovulation induction
Papaleo, E., Unfer, V., Baillargeon, J.-P., De Santis, L., Fusi, F., Brigante, C., Marelli, G., Cino, I., Redaelli, A., & Ferrari, A. (2007) · Gynecological Endocrinology · doi:10.1080/09513590701672405 · Cited by 185 · cited 2×
“In a study by Papaleo [99] there was a beneficial effect on restoration and maintenance of normal menstrual cycle during 6 months of MI treatment.”
BackgroundMethodDiamanti‐Kandarakis, E., & Panidis, D. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02954.x · Cited by 183 · cited 1×
“Biochemical hyperandrogenemia seen in PCOS shows positive correlation to the indices of insulin resistance in women with PCOS [30].”
BackgroundFundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions
Aversa, A., Vignera, S. L., Rago, R., Gambineri, A., Nappi, R. E., Calogero, A. E., & Ferlin, A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00516 · Cited by 183 · cited 2×
“None of the diagnostic criteria include however the metabolic disturbances (insulin resistance and overweight/obesity), that are often found in PCOS patients and could play a crucial role in the pathogenesis of the syndrome [2,3,5,7,9].”
BackgroundInositols in Insulin Signaling and Glucose Metabolism
Bevilacqua, A., & Bizzarri, M. (2018) · International Journal of Endocrinology · doi:10.1155/2018/1968450 · Cited by 165 · cited 4×
“Inositols are chemically identified as hexahydroxycyclohexanes and include a family of nine stereoisomers [59].”
BackgroundInfluentialCorrado, F., D’Anna, R., Di Vieste, G., Giordano, D., Pintaudi, B., Santamaria, A., & Di Benedetto, A. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03284.x · Cited by 162 · cited 1×
“In patients with already diagnosed gestational diabetes there was an improvement in glucose homeostasis measurements (fasting glucose and insulin, and consequently HOMA index) after MI treatment [122].”
Background(2009) · PubMed · Cited by 160
Artini, P. G., Di Berardino, O. M., Papini, F., Genazzani, A. D., Simi, G., Ruggiero, M., & Cela, V. (2013) · Gynecological Endocrinology · doi:10.3109/09513590.2012.743020 · Cited by 154 · cited 2×
“MI 1200–4000 mg daily [77,78,81] • Improved insulin sensitivity • Reduced BMI • Decreased testosterone levels • Decreased plasma LH levels and LH/FSH ratio • Decreased FG score • Improved menstrual cycle • Improved ovulation rate”
BackgroundEffects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials
Unfer, V., Nestler, J. E., Kamenov, Z. A., Prapas, N., & Facchinetti, F. (2016) · International Journal of Endocrinology · doi:10.1155/2016/1849162 · Cited by 151 · cited 1×
“MI and DCI have a significant role in glucose metabolism—MI participates in the cellular uptake of glucose, inducing the GLUT4 translocation to cell membrane [65]; inhibits the adenylate cyclase enzyme; and reduces the release of free fatty acids from adipose tissues, while DCI participates in glycogen synthesis [66]…”
BackgroundSelf-citationAltered D-Chiro-Inositol Urinary Clearance in Women With Polycystic Ovary Syndrome
Baillargeon, J.-P., Diamanti-Kandarakis, E., Ostlund, R. E., Apridonidze, T., Iuorno, M. J., & Nestler, J. E. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1070 · Cited by 146 · cited 1×
“Ovarian granulosa and theca cells, isolated form anovulatory PCOS patients show normal response to insulin [38,41,42].”
BackgroundCONWAY, G. S., JACOBS, H. S., HOLLY, J. M. P., & WASS, J. A. H. (1990) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1990.tb03897.x · Cited by 145
The D-chiro-inositol paradox in the ovary
Carlomagno, G., Unfer, V., & Roseff, S. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.05.027 · Cited by 139 · cited 1×
“who hypothesize that in the ovaries of polycystic ovary syndrome patients, enhanced epimerase activity leads to a local MI deficiency which in turn is responsible for the poor oocyte quality [73].”
BackgroundDucluzeau, P.-H., Cousin, P., Malvoisin, E., Bornet, H., Vidal, H., Laville, M., & Pugeat, M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030219 · Cited by 137
Nestler, J. E., & Jakubowicz, D. J. (1998) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199805000-00018 · Cited by 135 · cited 2×
“Insulin can directly stimulate androgen secretion and/or increase lutein hormone (LH)-induced androgen secretion from the theca-cells [35,36], increase the amplitude of LH pulsatile secretion [34], decrease liver production of sex hormone binding globulin (SHBG) [37] (Figure 1).”
BackgroundPhysiological and Pathological Androgen Actions in the Ovary
Astapova, O., Minor, B. M. N., & Hammes, S. R. (2019) · Endocrinology · doi:10.1210/en.2019-00101 · Cited by 133
D'Anna, R., Di Benedetto, A., Scilipoti, A., Santamaria, A., Interdonato, M. L., Petrella, E., Neri, I., Pintaudi, B., Corrado, F., & Facchinetti, F. (2015) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000000958 · Cited by 131
Moran, L., Gibson-Helm, M., Teede, H., & Deeks, A. (2010) · Journal of Psychosomatic Obstetrics & Gynecology · doi:10.3109/01674820903477593 · Cited by 127
Gerli, S., Mignosa, M., & Renzo, G. C. D. (2003) · PubMed · Cited by 125
Soldani, R., Cagnacci, A., & Yen, S. S. (1994) · European Journal of Endocrinology · doi:10.1530/eje.0.1310641 · Cited by 121 · cited 1×
“Insulin increases both basal and GNRH-stimulated secretion of LH and FSH in isolated pituitary cell cultures [50,51], but not in vivo [52].”
BackgroundIncreased Luteinizing Hormone Sensitivity to Dopamine Inhibition in Polycystic Ovary Syndrome*
QUIGLEY, M. E., RAKOFF, J. S., & YEN, S. S. C. (1981) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-52-2-231 · Cited by 114
Matarrelli, B., Vitacolonna, E., D’angelo, M., Pavone, G., Mattei, P. A., Liberati, M., & Celentano, C. (2013) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2013.766691 · Cited by 114
Santamaria, A., Di Benedetto, A., Petrella, E., Pintaudi, B., Corrado, F., D’Anna, R., Neri, I., & Facchinetti, F. (2016) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2015.1121478 · Cited by 114
Female infertility: which role for obesity?
on behalf of the Obesity Programs of nutrition, E., Gambineri, A., Laudisio, D., Marocco, C., Radellini, S., Colao, A., & Savastano, S. (2019) · International Journal of Obesity Supplements · doi:10.1038/s41367-019-0009-1 · Cited by 114
(2012) · PubMed · Cited by 111
Ek, I., Arner, P., Bergqvist, A., Carlström, K., & Wahrenberg, H. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.4.3899 · Cited by 110 · cited 1×
“Insulin can directly stimulate androgen secretion and/or increase lutein hormone (LH)-induced androgen secretion from the theca-cells [35,36], increase the amplitude of LH pulsatile secretion [34], decrease liver production of sex hormone binding globulin (SHBG) [37] (Figure 1).”
BackgroundMetabolism and Ovarian Function in PCOS Women: A Therapeutic Approach with Inositols
Laganà, A. S., Rossetti, P., Buscema, M., La Vignera, S., Condorelli, R. A., Gullo, G., Granese, R., & Triolo, O. (2016) · International Journal of Endocrinology · doi:10.1155/2016/6306410 · Cited by 109 · cited 1×
“In 2015 International Consensus Conference on MI and DCI in Obstetrics and Gynecology recognizes that both MI and DCI are involved in several biological pathways, involved in PCOS pathogenesis and there is plenty clinical data demonstrating that inositols supplementation could be beneficial for improving metabolic and…”
BackgroundInvolvement of Inositol in Reproduction
Beemster, P., Groenen, P., & Steegers-Theunissen, R. (2002) · Nutrition Reviews · doi:10.1301/00296640260042748 · Cited by 106 · cited 1×
“MI can also be actively synthetized (up to 4 g/day) in human body (especially the liver and brain) [61].”
BackgroundCUMMING, D. C., REID, R. L., QUIGLEY, M. E., REBAR, R. W., & YEN, S. S. C. (1984) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1984.tb00114.x · Cited by 106 · cited 1×
“Tonic hypersecretion of LH in PCOS patients could be at least partially related to decreased dopaminergic and opioid tonus [46,47].”
BackgroundUnfer, V., Carlomagno, G., Papaleo, E., Vailati, S., Candiani, M., & Baillargeon, J.-P. (2014) · Reproductive Sciences · doi:10.1177/1933719113518985 · Cited by 105 · cited 2×
“In patients with PCOS and insulin resistance, hyperinsulinemia induces higher DCI-to-MI ratio because of stimulated epimerase activity, which transforms MI to DCI [69].”
BackgroundInsulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women
Raffone, E., Rizzo, P., & Benedetto, V. (2010) · Gynecological Endocrinology · doi:10.3109/09513590903366996 · Cited by 100 · cited 2×
“patients restored spontaneous ovulation activity, compared to 50% of metformin-treated patients [101].”
MethodResultBenelli, E., Del Ghianda, S., Di Cosmo, C., & Tonacchera, M. (2016) · International Journal of Endocrinology · doi:10.1155/2016/3204083 · Cited by 100 · cited 17×
“In a small patient cohort (n = 40) De Cicco et al. [129] demonstrated that the combination of MI +ALA for 6 months decreased BMI, waist-hip ratio, hirsutism score, AMH, ovarian volume, and antral follicle count, and an increase in the number of menstrual cycles.”
BackgroundInfluentialCabrera-Cruz, H., Oróstica, L., Plaza-Parrochia, F., Torres-Pinto, I., Romero, C., & Vega, M. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00162.2019 · Cited by 98 · cited 4×
“t I I s i s li - i etic r erties ecre se st ra ial l l c se ile l c se eta lis is s ifte t ar l c e s t esis I, a t ar l c se cata lis I [67].”
BackgroundInfluentialMyo-inositol may prevent gestational diabetes in PCOS women
D’Anna, R., Di Benedetto, V., Rizzo, P., Raffone, E., Interdonato, M. L., Corrado, F., & Di Benedetto, A. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2011.633665 · Cited by 95
Facchinetti, F., Orrù, B., Grandi, G., & Unfer, V. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1540578 · Cited by 94
Ciaraldi, T. P., Morales, A. J., Hickman, M. G., Odom-Ford, R., Olefsky, J. M., & Yen, S. S. C. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.5.3961 · Cited by 92
Zacchè, M. M., Caputo, L., Filippis, S., Zacchè, G., Dindelli, M., & Ferrari, A. (2009) · Gynecological Endocrinology · doi:10.1080/09513590903015544 · Cited by 91 · cited 3×
“MI 1200–4000 mg daily [77,78,81] • Improved insulin sensitivity • Reduced BMI • Decreased testosterone levels • Decreased plasma LH levels and LH/FSH ratio • Decreased FG score • Improved menstrual cycle • Improved ovulation rate”
BackgroundMethodDonà, G., Sabbadin, C., Fiore, C., Bragadin, M., Giorgino, F. L., Ragazzi, E., Clari, G., Bordin, L., & Armanini, D. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0840 · Cited by 89 · cited 2×
“MI 1200–4000 mg daily [77,78,81] • Improved insulin sensitivity • Reduced BMI • Decreased testosterone levels • Decreased plasma LH levels and LH/FSH ratio • Decreased FG score • Improved menstrual cycle • Improved ovulation rate”
BackgroundGenazzani, A. D., Prati, A., Santagni, S., Ricchieri, F., Chierchia, E., Rattighieri, E., Campedelli, A., Simoncini, T., & Artini, P. G. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2012.685205 · Cited by 88 · cited 2×
“[91] showed a nonsignificant change of BMI, although improvement of other PCOS-related parameters was improved.”
ResultBevilacqua, A., Dragotto, J., Giuliani, A., & Bizzarri, M. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27623 · Cited by 84 · cited 1×
“In the experimental (mice) model of PCOS, MI/DCI treatment in a 40:1 ratio made a fast recovery from PCOS signs and symptoms, while other MI/DCI ratios were less effective or had even negative effects [111].”
MethodPORETSKY, L., GLOVER, B., LAUMAS, V., KALIN, M., & DUNAIF, A. (1988) · Endocrinology · doi:10.1210/endo-122-2-581 · Cited by 80 · cited 1×
“Insulin increases both basal and GNRH-stimulated secretion of LH and FSH in isolated pituitary cell cultures [50,51], but not in vivo [52].”
BackgroundKamenov, Z., Kolarov, G., Gateva, A., Carlomagno, G., & Genazzani, A. D. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2014.964640 · Cited by 80 · cited 1×
“[104] most of the patients resistant to MI were obese.”
BackgroundSelf-citationInsulin-Lowering Drugs In Polycystic Ovary Syndrome
Iuorno, M. J., & Nestler, J. E. (2001) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(05)70191-1 · Cited by 79 · cited 1×
“Few years later the same effects were demonstrated in lean PCOS women [76], where the area under the plasma insulin curve after oral administration of glucose decreased significantly and serum-free testosterone concentration decreased by 73% in comparison with essentially no change in the placebo group.”
Background(2019) · PubMed · doi:10.26355/eurrev_201906_18223 · Cited by 75 · cited 2×
“5:1; 5:1; 20:1; 80:1), especially when the 40:1 ratio was modified in favor of DCI [112].”
BackgroundEk, I. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.4.1147 · Cited by 75
Regidor, P.-A., Schindler, A. E., Lesoine, B., & Druckman, R. (2018) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0067 · Cited by 74
Ciaraldi, T. P. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.5.1421 · Cited by 72
Legro, R. S., Kunselman, A. R., Dodson, W. C., & Dunaif, A. (1999) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199906000-00019 · Cited by 71 · cited 1×
“Current evidence suggests that insulin resistance and compensatory hyperinsulinemia are a central feature of PCOS [14].”
BackgroundAgrawal, A., Mahey, R., Kachhawa, G., Khadgawat, R., Vanamail, P., & Kriplani, A. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1549656 · Cited by 70 · cited 1×
“03) than metformin alone while the effect of fasting blood glucose and insulin levels was not statistically different [88].”
BackgroundMasharani, U., Gjerde, C., Evans, J. L., Youngren, J. F., & Goldfine, I. D. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400218 · Cited by 65 · cited 1×
“The combination between DCI and ALA did not significantly improve the clinical and metabolic disturbances in PCOS patents [125], although other studies show some benefits of ALA on glucose uptake in lean PCOS patients [126].”
ResultPolycystic ovary syndrome and risk factors for gestational diabetes
Mustaniemi, S., Vääräsmäki, M., Eriksson, J. G., Gissler, M., Laivuori, H., Ijäs, H., Bloigu, A., Kajantie, E., & Morin-Papunen, L. (2018) · Endocrine Connections · doi:10.1530/ec-18-0076 · Cited by 65
Shokrpour, M., Foroozanfard, F., Afshar Ebrahimi, F., Vahedpoor, Z., Aghadavod, E., Ghaderi, A., & Asemi, Z. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1540570 · Cited by 63 · cited 15×
“In a small patient cohort (n = 40) De Cicco et al. [129] demonstrated that the combination of MI +ALA for 6 months decreased BMI, waist-hip ratio, hirsutism score, AMH, ovarian volume, and antral follicle count, and an increase in the number of menstrual cycles.”
BackgroundInfluentialFacchinetti, F., Appetecchia, M., Aragona, C., Bevilacqua, A., Bezerra Espinola, M. S., Bizzarri, M., D’Anna, R., Dewailly, D., Diamanti-Kandarakis, E., Hernández Marín, I., et al. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1737675 · Cited by 63 · cited 2×
“Polycystic ovary syndrome is a primary risk factor for adverse pregnancy outcomes [66].”
BackgroundSelf-citationMinozzi, M., Nordio, M., & Pajalich, R. (2013) · PubMed · Cited by 62
Myo-Inositol in the Treatment of Teenagers Affected by PCOS
Pkhaladze, L., Barbakadze, L., & Kvashilava, N. (2016) · International Journal of Endocrinology · doi:10.1155/2016/1473612 · Cited by 62
Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women
Montanino Oliva, M., Buonomo, G., Calcagno, M., & Unfer, V. (2018) · Journal of Ovarian Research · doi:10.1186/s13048-018-0411-2 · Cited by 62
The inositols and polycystic ovary syndrome
Kalra, S., Kalra, B., & Sharma, J. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.189231 · Cited by 59 · cited 1×
“This can explain why DCI supplementation produces an increase in testosterone levels and concomitant reduction of estrogens [72].”
BackgroundEffectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis
Zeng, L., & Yang, K. (2018) · Endocrine · doi:10.1007/s12020-017-1442-y · Cited by 59
Morgante, G., Orvieto, R., Sabatino, A. D., Musacchio, M. C., & Leo, V. D. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.01.035 · Cited by 57 · cited 1×
“40%) and improvement in clinical pregnancy rate in patients with PCOS and insulin resistance, undergoing gonadotropin ovulation induction [106].”
BackgroundMinozzi, M., Costantino, D., Guaraldi, C., & Unfer, V. (2011) · Gynecological Endocrinology · doi:10.3109/09513590.2011.564685 · Cited by 56
Cianci, A., Panella, M., Fichera, M., Falduzzi, C., Bartolo, M., & Caruso, S. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1014784 · Cited by 51 · cited 1×
“The combination between DCI and ALA did not significantly improve the clinical and metabolic disturbances in PCOS patents [125], although other studies show some benefits of ALA on glucose uptake in lean PCOS patients [126].”
ResultAltered Ovarian Inositol Ratios May Account for Pathological Steroidogenesis in PCOS
Unfer, V., Dinicola, S., Laganà, A. S., & Bizzarri, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197157 · Cited by 50 · cited 3×
“Some studies have demonstrated that MI treatment in patients with PCOS improved ovarian function and fertility [98–109], decreased the severity of hyperandrogenism, acne, and hirsutism [78,96,102], and positively affected metabolic parameters and modulated various hormonal parameters deeply involved in the reproductiv…”
BackgroundMethodResultFulghesu, A. M., Angioni, S. L., Portoghese, E., Milano, F., Batetta, B., Paoletti, A. M., & Melis, G. B. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.01.024 · Cited by 49
Chukwuma, C. I., Ibrahim, M. A., & Islam, M. S. (2016) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-016-0517-1 · Cited by 49 · cited 1×
“On the one hand MI inhibits duodenal glucose absorption and reduces blood glucose rise, suggesting the existence of a competitive affinity for the same transporter system [59,62].”
BackgroundPolycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols
Sortino, M. A., Salomone, S., Carruba, M. O., & Drago, F. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00341 · Cited by 49
Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary
Roseff, S., & Montenegro, M. (2020) · International Journal of Endocrinology · doi:10.1155/2020/6461254 · Cited by 49 · cited 1×
“On the other hand DCI was found to be an aromatase inhibitor which increases androgens and may have harmful consequences for normal ovulatory function [115].”
BackgroundAdvani, K., Batra, M., Tajpuriya, S., Gupta, R., Saraswat, A., Nagar, H. D., Makwana, L., Kshirsagar, S., Kaul, P., Ghosh, A. K., et al. (2019) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2019.1604644 · Cited by 48 · cited 1×
“A recent study showed that the combination of insulin-sensitizing agents (MI, DCI, and chromium picolinate), antioxidants, and vitamins leads to improvements in menstrual cyclicity, acne, and hirsutism in both obese and lean PCOS patients [134].”
BackgroundReproductive impact of polycystic ovary syndrome
Usadi, R., & Legro, R. S. (2012) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328359ff92 · Cited by 47 · cited 1×
“It is a major cause of menstrual disturbances, hirsutism, and female anovulatory infertility [4].”
BackgroundVigil, P., Contreras, P. H., Alvarado, J. L., Godoy, A., Salgado, A. M., & Cortés, M. E. (2007) · Human Reproduction · doi:10.1093/humrep/dem302 · Cited by 47 · cited 2×
“Although the insulin resistance is thought to be fundamental for PCOS, obesity tends to worsen it and the accompanying metabolic disturbances [23,24] and contributes to the prevalence of the metabolic syndrome in PCOS patients [25].”
BackgroundResultJanuszewski, M., Issat, T., Jakimiuk, A. A., Santor-Zaczyńska, M., & Jakimiuk, A. J. (2019) · Ginekologia Polska · doi:10.5603/gp.2019.0002 · Cited by 47
Regidor, P.-A., & Schindler, A. E. (2016) · International Journal of Endocrinology · doi:10.1155/2016/9537632 · Cited by 44
Cirillo, F., Catellani, C., Lazzeroni, P., Sartori, C., Tridenti, G., Vezzani, C., Fulghesu, A. M., Madeddu, E., Amarri, S., & Street, M. E. (2020) · Gynecological Endocrinology · doi:10.1080/09513590.2020.1725967 · Cited by 44
Genazzani, A. D., Prati, A., Marchini, F., Petrillo, T., Napolitano, A., & Simoncini, T. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2019.1640200 · Cited by 42 · cited 1×
“A recent retrospective study evaluated the effects of MI (1 g/day per os), alpha-lipoic acid (400 mg/day per os), and a combination of both in 90 overweight/obese patients with PCOS [132].”
BackgroundTroisi, J., Cinque, C., Giugliano, L., Symes, S. J. K., Richards, S. M., Adair, D. C., Cavallo, P., Sarno, L., Scala, G., Caiazza, M., et al. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0500-x · Cited by 40 · cited 1×
“25 g/day), and glucomannan (a water-soluble fiber that is derived from the konjac root) (4 g/day) [136].”
Background(2019) · PubMed · doi:10.26355/eurrev_201903_17278 · Cited by 38 · cited 2×
“8 mg DCI and 200 μg folic acid, per day) showed a significant decrease in weight, BMI, waist and hip circumferences decreased significantly in all the patients [94].”
BackgroundResultCicco, S. D., Immediata, V., Romualdi, D., Policola, C., Tropea, A., Florio, C. D., Tagliaferri, V., Scarinci, E., Casa, S. D., Lanzone, A., et al. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1313972 · Cited by 37 · cited 1×
“[129] demonstrated that the combination of MI +ALA for 6 months decreased BMI, waist-hip ratio, hirsutism score, AMH, ovarian volume, and antral follicle count, and an increase in the number of menstrual cycles.”
BackgroundUterine Function: From Normal to Polycystic Ovarian Syndrome Alterations
Ferreira, S. R., & Motta, A. B. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867325666171205144119 · Cited by 37
Mendoza, N., Diaz-Ropero, M. P., Aragon, M., Maldonado, V., Llaneza, P., Lorente, J., Mendoza-Tesarik, R., Maldonado-Lobon, J., Olivares, M., & Fonolla, J. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2019.1576620 · Cited by 36
Ozay, A. C., Emekci Ozay, O., Okyay, R. E., Cagliyan, E., Kume, T., & Gulekli, B. (2016) · International Journal of Endocrinology · doi:10.1155/2016/3206872 · Cited by 34 · cited 3×
“In another study progesterone and AMH levels, ovarian volume, ovarian antral follicle, and total antral follicle counts decreased significantly both in MI and combined contraceptive-treated patients with PCOS [97].”
BackgroundJamilian, M., Farhat, P., Foroozanfard, F., Afshar Ebrahimi, F., Aghadavod, E., Bahmani, F., Badehnoosh, B., Jamilian, H., & Asemi, Z. (2017) · Clinical Endocrinology · doi:10.1111/cen.13366 · Cited by 31 · cited 1×
“The trials assessing this combination show improved reproductive [100], hormonal, and metabolic disturbances in PCOS patients [95,97,108,123].”
BackgroundFruzzetti, F., Capozzi, A., Canu, A., & Lello, S. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1540573 · Cited by 31 · cited 1×
“One study that evaluated the effects of the combination of DCI and alpha lipoic acid (1000 mg DCI and 600 mg alpha lipoic acid daily) on menstrual cycle and insulin sensitivity in 41 women with polycystic ovary syndrome and 31 controls found that the association of DCI and alpha lipoic acid improves menstrual cycle le…”
BackgroundCammarata, P. R., Chen, H. Q., Yang, J., & Yorio, T. (1992) · PubMed · Cited by 29
Cardiovascular Risk Factors in Bulgarian Patients with Polycystic Ovary Syndrome and/or Obesity
Gateva, A., & Kamenov, Z. A. (2012) · Obstetrics and Gynecology International · doi:10.1155/2012/306347 · Cited by 29 · cited 2×
“According to our data there is also some differences in diagnostic value of different methods for diagnosing insulin resistance between lean and obese PCOS subjects [20].”
BackgroundSelf-citationFacchinetti, F., Dante, G., & Neri, I. (2016) · ISGE Series · doi:10.1007/978-3-319-23865-4_13 · Cited by 28 · cited 1×
“Under physiological conditions, the MI/DCI ratio is between 100:1 in the follicular fluid and 40:1 in plasma [69,70].”
BackgroundMendoza, N., Galan, M. I., Molina, C., Mendoza‐Tesarik, R., Conde, C., Mazheika, M., Díaz-Ropero, M. P., Fonollá, J., Tesařík, J., & Olivares, M. M. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2019.1681959 · Cited by 28 · cited 1×
“5:1; 5:1; 20:1; 80:1 (total daily dose 2000 mg) [112] 2:1 (500 mg + 300 mg) [114] 3:1 (550 mg+150 mg) • Decreased blood glucose • Decreased insulin levels • Decreased BMI • Decreased testosterone levels • Decreased FSH, LH levels • Increased SHBG concentrations • Higher pregnancy rate • positive effect on the “cytopla…”
BackgroundLow levels of sex hormone-binding globulin in obese children
Dunkel, L., Sorva, R., & Voutilainen, R. (1985) · The Journal of Pediatrics · doi:10.1016/s0022-3476(85)80623-5 · Cited by 27 · cited 1×
“Increased insulin levels act synergistically with LH to stimulate ovarian production of androgens [38,48] and suppresses SHBG production from the liver [49], that leads to increased free testosterone levels.”
BackgroundDonne, M. L., Alibrandi, A., Giarrusso, R., Monaco, I., & Muraca, U. (2012) · PubMed · Cited by 24
Fruzzetti, F., Fidecicchi, T., Palla, G., & Gambacciani, M. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2019.1640673 · Cited by 24
Myo-inositol transport into endothelial cells derived from nervous system microvessels
Kollros, P. E., Goldstein, G. W., & Betz, A. L. (1990) · Brain Research · doi:10.1016/0006-8993(90)90170-g · Cited by 23 · cited 1×
“glucose and inositol uptake [64], suggesting that the two molecules share the transporter system(s) [59].”
BackgroundMarkers of visceral obesity and cardiovascular risk in patients with polycystic ovarian syndrome
Gateva, A., & Kamenov, Z. A. (2012) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2012.05.037 · Cited by 22 · cited 1×
“Although the insulin resistance is thought to be fundamental for PCOS, obesity tends to worsen it and the accompanying metabolic disturbances [23,24] and contributes to the prevalence of the metabolic syndrome in PCOS patients [25].”
BackgroundSelf-citationMetabolic impact of current therapeutic strategies in Polycystic Ovary Syndrome: a preliminary study
Diego, M. V. D., Gómez-Pardo, O., Kirk-Grohar, J., López‐Escobar, A., Martín‐Estal, I., Castilla‐Cortázar, I., & Rodríguez‐Zambrano, M. Á. (2020) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-020-05696-y · Cited by 22 · cited 1×
“A more recent study that compares inositols to other treatment strategies (COC and metformin) shows that inositol therapies (either MI + folic acid or MI + DCI + folic acid) improved significantly insulin resistance and glycosylated hemoglobin, reducing cholesterol and triglyceride levels and blood pressure (when used…”
ResultArtini, P. G., Obino, M. E. R., Micelli, E., Malacarne, E., Vacca, C., Papini, F., & Cela, V. (2020) · Gynecological Endocrinology · doi:10.1080/09513590.2020.1737007 · Cited by 18
Wdowiak, A., & Filip, M. (2020) · PubMed · doi:10.26355/eurrev_202008_22649 · Cited by 18 · cited 1×
“24% in the control group, that received only 200 μg folic acid twice a day [138].”
BackgroundLangdon, D. R. (1999) · Clinical Pediatrics · doi:10.1177/000992289903800409 · Cited by 16
Handbook of Vitamins: Nutritional, Biochemical, and Clinical Aspects
Halsted, C. H. (1987) · Journal of Nutrition · doi:10.1093/jn/117.2.397 · Cited by 16
Fruzzetti, F., Benelli, E., Fidecicchi, T., & Tonacchera, M. (2020) · International Journal of Endocrinology · doi:10.1155/2020/2901393 · Cited by 16 · cited 1×
“Another study aimed to evaluate the effects of a treatment with α-lipoic acid (800 mg per day) in combination with two different doses of MI on clinical and metabolic features in 71 women with PCOS—43 patients received 2000 mg of MI and 28 received 1000 mg of MI per day [131].”
MethodEfficacy of the synergic action of myoinositol, tyrosine, selenium and chromium in women with PCOS.
Oliva, M. M., Zuev, V., Lippa, A., Carrà, M., & Lisi, F. (2019) · PubMed · doi:10.26355/eurrev_201910_19186 · Cited by 9 · cited 1×
“2 mg folic acid, 55 mcg selenium, 40 mcg chromium [135].”
Background
Research works printed but not linked: 4
- Ciotta, L., Iozza, I., Rubbino, G., Iemmola, A., Lizzio, I., Teodoro, M.C., and Palumbo, M. (2010, January 4–7). Treatment of hyperandrogenism by myo-inositol. Proceedings of the 14th World Congress of Gynecological Endocrinology, Firenze, Italy.
- Di Berardino, O.M., Monteleone, P., Valentino, V., Ruggiero, M., Papini, F., Cela, V., Artini, P.G., and Genazzani, A.R. (2010, January 4–7). Myo-inositol administration in pcos patients after IVF. Proceedings of the 14th World Congress of Gynecological Endocrinology, Firenze, Italy.
- Papaleo, E., De Santis, L., Baillargeon, J., Zacche, M., Fusi, F., Brigante, C., and Ferrari, A. (2008, January 6–9). Comparison of myo-inositol plus folic acid vs clomiphene citrate for first line treatment in women with polycystic ovary syndrome. Proceedings of the 24th Annual Meeting of ESHRE, Barcelona, Spain.
- Genazzani, 2020, Expert’s opinion: Integrative treatment with inositols and lipoic acid for insulin resistance of PCOS. Gynecol, Reprod. Endocrinol. Metab., 1, 146
Cited by
Contreras-Bolívar, V., García-Fontana, B., García-Fontana, C., & Muñoz-Torres, M. (2021) · Nutrients · doi:10.3390/nu13103491 · Cited by 226
Mitochondrial Dysfunction and Chronic Inflammation in Polycystic Ovary Syndrome
Dabravolski, S. A., Nikiforov, N. G., Eid, A. H., Nedosugova, L. V., Starodubova, A. V., Popkova, T. V., Bezsonov, E. E., & Orekhov, A. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083923 · Cited by 207
Calcaterra, V., Verduci, E., Cena, H., Magenes, V. C., Todisco, C. F., Tenuta, E., Gregorio, C., De Giuseppe, R., Bosetti, A., Di Profio, E., et al. (2021) · Nutrients · doi:10.3390/nu13061848 · Cited by 183
“Among them, inositol [166,167] has been shown to provide benefits for subjects with PCOS, improving IR and reducing the secretion of triglycerides.”
BackgroundPolycystic ovarian syndrome-current pharmacotherapy and clinical implications
Rashid, R., Mir, S. A., Kareem, O., Ali, T., Ara, R., Malik, A., Amin, F., & Bader, G. N. (2022) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2021.11.009 · Cited by 156
Inositols: From Established Knowledge to Novel Approaches
Dinicola, S., Unfer, V., Facchinetti, F., Soulage, C. O., Greene, N. D., Bizzarri, M., Laganà, A. S., Chan, S.-Y., Bevilacqua, A., Pkhaladze, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910575 · Cited by 154
“However, 25% to 75% of patients treated with myo-Ins may still be resistant to treatment [171].”
BackgroundSelf-citation
Metadata
- Authors
- Kamenov, Z., & Gateva, A.
- Affiliations
- Alexandrovska Hospital (BG)
- Corresponding author
- Kamenov, Zdravko
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-11-27
- Volume
- 25
- Issue
- 23
- Pages
- 5566
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7729761
- OpenAlex
- W3109824023
- Cited by
- 100
- References
- 147
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 15 · 2023: 29 · 2022: 14 · 2021: 12
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- polycystic ovary syndrome, myo-inositol, D-chiro-inositol, insulin resistance, hyperandrogenism, hirsutism, acne, ovulation induction, ovarian function, fertility, insulin signaling, metabolic outcomes
- MeSH terms
- Animals, Female, Humans, Inositol, Ovulation, Polycystic Ovary Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.